Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum…
News
VectivBio to Participate at the Bank of America 2022 Healthcare Conference
BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) — VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a…
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”, or “the Company”) (TSX:RVX),…
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30…
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b…
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential commercial…
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
– Initial data from Phase 1b trial of FTX-6058 in sickle cell disease to be…
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
–Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral…
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
– THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review – –…
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones
Preclinical data to be presented at the American Society of Gene & Cell Therapy 25th…
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:…
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
Hear about the study London, UK – 9 May 2022 COMPASS Pathways plc (Nasdaq: CMPS)…
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights
Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with…
TELA Bio to Participate in Upcoming 2022 H.C. Wainwright Annual Global Investment Conference
MALVERN, Pa., May 09, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical…
Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)
Preclinical data show investigational intravitreal long-acting PASylated-nomacopan (PAS-nomacopan) effective in inhibiting choroidal neovascularization (CNV), which…
Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022
DURHAM, N.C., May 09, 2022 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it…
Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
Fibromyalgia Phase 3 Trial of TNX-102 SL Enrollment Initiated; Results from Interim Analysis Expected First…
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
– Study duration increased from 6 months to 18 months of open label treatment with…
Amicus Therapeutics Announces First Quarter 2022 Financial Results
1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold®…
Trevena to Release First Quarter 2022 Financial Results on May 11, 2022
Company to host a Conference Call & Webcast at 8:00 a.m. ET CHESTERBROOK, Pa., May…